Cite

HARVARD Citation

    T Danley, K. et al. (2021). A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation. Oncologist. pp. 811-817. [Online]. 
  
Back to record